ѻý

<ѻý class="page-title">Meeting Coverage

GuCS

<ѻý class="page-description">Genitourinary Cancers Symposium
First-Line Combo for Cisplatin-Ineligible Bladder Cancer Just Misses Positive Result

Cabozantinib-pembrolizumab induced responses in 16 of 35 evaluable patients, but needed one more

GuCS over a photo of Moscone Convention Center West in San Francisco, CA
<ѻý class="section_title">Latest GuCS Meeting Coverage
More Evidence That ARSIs for Prostate Cancer Differ in Cognitive Effects

More fatigue, depression, worse reaction time with enzalutamide as compared with abiraterone

January 29, 2024
A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma

Pembrolizumab leads to improved OS; single-agent nivolumab fails to impact DFS

January 28, 2024
Another Prostate Cancer Screening Candidate Outperforms Standard PSA Testing

Multiparametric Stockholm3 avoided far more unnecessary biopsies without sacrificing sensitivity

January 28, 2024
Adjuvant Pembrolizumab Boosts DFS in High-Risk Muscle Invasive Urothelial Cancer

Benefit more than double with the immune checkpoint inhibitor compared with observation

January 28, 2024
Cabozantinib Plus Atezolizumab Delays Progression in mCRPC

Combination improved PFS versus more hormonal therapy, but control arm questioned

January 26, 2024
Olaparib-Abiraterone in Biomarker-Selected mCRPC Tops Each Agent Alone

In small first-line trial, PFS more than doubled with combination

January 26, 2024
Study Supports High-Dose RT, Long-Term ADT as Standard for High-Risk Prostate Cancer

OS, PFS, cancer-specific survival all improved, with no increase in toxicity

January 26, 2024
ICI/TKI Combo Maintains Survival Benefit in Advanced RCC

Updated trial data show nivolumab/cabozantinib doublet "is getting better with age"

February 20, 2023
Pembrolizumab Active in BCG-Unresponsive Papillary High-Risk Bladder Cancer

KEYNOTE-057 trial results suggest DFS benefit for patient population with unmet need

February 19, 2023
Escalated ADT Falls Short in Men With High-Risk Features After Prostatectomy

But add-on abiraterone and apalutamide may offer some benefits in those with higher PSA

February 18, 2023
Add-On Olaparib Continues to Show Benefit in First-Line Treatment of mCRPC

Final PROpel analysis also shows trend toward overall survival improvement with PARP inhibitor

February 17, 2023
Adding Talazoparib to Enzalutamide Boosts PFS in Metastatic Prostate Cancer

Combination achieved a 37% reduction in risk of progression, death versus ARPI alone

February 17, 2023
Rucaparib Gets a Win in Metastatic Castration-Resistant Prostate Cancer

Benefit in selected patients seen over physician's choice of docetaxel or second-generation ARPI

February 16, 2023
PD-L1 Inhibitor Fails to Meet PFS Target in Advanced Penile Cancer

Atezolizumab did show some activity, with a 30% overall response rate

February 22, 2022
<ѻý class="section_title">Videos
GuCS Video Pearls
February 2024